PIK3CB encodes the p110β catalytic subunit of class I phosphoinositide 3-kinase (PI3K), which phosphorylates phosphatidylinositol 4,5-bisphosphate to generate PIP3, a critical second messenger that activates downstream signaling cascades including AKT and mTOR pathways involved in cell growth, survival, and proliferation 1. The enzyme plays essential roles in platelet adhesion and aggregation, autophagy initiation, and cellular responses to G-protein coupled receptor and growth factor stimulation 1. PIK3CB demonstrates both kinase-dependent and kinase-independent functions, including scaffolding roles in insulin signaling and endocytosis 1. In cancer, PIK3CB is frequently upregulated and contributes to oncogenic transformation, particularly in PTEN-deficient tumors that rely on p110β activity for sustained proliferation 12. The gene shows prognostic significance across multiple cancer types, with high expression correlating with poor patient survival and multidrug resistance 23. PIK3CB can be transcriptionally activated by RNA-binding proteins like hnRNPL through phase separation mechanisms, promoting glycolysis and tumor progression in ovarian cancer 4. Recent studies have identified rare oncogenic mutations in PIK3CB that enhance tumorigenic potential 5, establishing it as both a biomarker and therapeutic target in cancer treatment.